BDTX Black Diamond Therapeutics, Inc.
Healthcare · Market cap: $84.5M
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $0 | $0 |
| 2022-Q2 | $3.0M | $0 |
| 2022-Q3 | $0 | $0 |
| 2022-Q4 | $1.3M | $0 |
| 2023-Q1 | $0 | $0 |
| 2023-Q2 | $14.6M | $167.5K |
| 2023-Q3 | $9.7M | $0 |
| 2023-Q4 | $936.0K | $0 |
| 2024-Q1 | $0 | $0 |
| 2024-Q2 | $0 | $0 |
| 2024-Q3 | $0 | $1.4M |
| 2024-Q4 | $0 | $0 |
| 2025-Q1 | $0 | $12.0M |
| 2025-Q2 | $0 | $0 |
| 2025-Q3 | $0 | $0 |
| 2025-Q4 | $0 | $0 |
| 2026-Q1 | $0 | $0 |
| 2026-Q2 | $0 | $0 |
| 2026-Q3 | $0 | $0 |
| 2026-Q4 | $0 | $0 |
Bought$29.5M20 buy days
Sold$13.6M3 sell days
Net insider flow+$15.9Mnet buying · 5 years
Latest trade2025-03-19BB BIOTECH AG
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2025-03-19 | Sell | BB BIOTECH AG | 10% owner | 5,784,292 | $2.07 | $12.0M | 7 |
| 2024-08-28 | Sell | Versant Venture Capital VI, L.P. | 10% owner | 221,600 | $6.32 | $1.4M | 1 |
| 2023-10-17 | Buy | BB BIOTECH AG | 10% owner | 400,000 | $2.34 | $936.0K | 1 |
| 2023-07-05 | Buy | Behbahani Ali | Director | 1,000,000 | $5.00 | $5.0M | 1 |
| 2023-07-05 | Buy | Kolchinsky Peter | Director | 935,850 | $5.00 | $4.7M | 1 |
| 2023-06-30 | Buy | BB BIOTECH AG | 10% owner | 1,000,000 | $5.00 | $5.0M | 1 |
| 2023-06-27 | Buy | BB BIOTECH AG | 10% owner | 1,740,000 | $5.49 | $9.6M | 1 |
| 2023-06-27 | Sell | Epstein David M. | Director | 25,000 | $6.70 | $167.5K | 1 |
| 2022-12-22 | Buy | Ni Fang | Other officer | 36,363 | $1.28 | $46.5K | 1 |
| 2022-12-21 | Buy | Ni Fang | Other officer | 20,000 | $1.29 | $25.8K | 1 |
| 2022-10-31 | Buy | BB BIOTECH AG | 10% owner | 99,801 | $2.25 | $224.6K | 1 |
| 2022-10-28 | Buy | BB BIOTECH AG | 10% owner | 172,974 | $2.18 | $377.1K | 1 |
| 2022-10-27 | Buy | BB BIOTECH AG | 10% owner | 191,678 | $1.87 | $358.4K | 1 |
| 2022-10-21 | Buy | BB BIOTECH AG | 10% owner | 87,850 | $1.51 | $132.7K | 1 |
| 2022-10-20 | Buy | BB BIOTECH AG | 10% owner | 53,734 | $1.42 | $76.3K | 1 |
| 2022-10-19 | Buy | BB BIOTECH AG | 10% owner | 77,689 | $1.32 | $102.5K | 1 |
| 2022-06-29 | Buy | Ni Fang | Other officer | 25,000 | $2.44 | $61.0K | 1 |
| 2022-04-28 | Buy | BB BIOTECH AG | 10% owner | 255,711 | $2.57 | $657.2K | 1 |
| 2022-04-27 | Buy | BB BIOTECH AG | 10% owner | 150,000 | $2.66 | $399.0K | 1 |
| 2022-04-19 | Buy | BB BIOTECH AG | 10% owner | 150,000 | $3.24 | $486.0K | 1 |
| 2022-04-18 | Buy | BB BIOTECH AG | 10% owner | 150,000 | $3.29 | $493.5K | 1 |
| 2022-04-13 | Buy | BB BIOTECH AG | 10% owner | 102,556 | $3.57 | $366.1K | 1 |
| 2022-04-12 | Buy | BB BIOTECH AG | 10% owner | 150,000 | $3.42 | $513.0K | 1 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| BB BIOTECH AG | 10% owner | $19.7M | $12.0M | 2025-03-19 |
| Behbahani Ali | Director | $5.0M | $0 | 2023-07-05 |
| Kolchinsky Peter | Director | $4.7M | $0 | 2023-07-05 |
| Versant Venture Capital VI, L.P. | 10% owner | $0 | $1.4M | 2024-08-28 |
| Epstein David M. | Director | $0 | $167.5K | 2023-06-27 |
| Ni Fang | Other officer | $133.3K | $0 | 2022-12-22 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2023-06-27 → 2023-07-05 | 3 | $24.2M | 54 | -30.7% (-26.1% raw) | -38.2% (-44.0% raw) | -47.2% (-39.7% raw) | closed |
| 2020-02-03 | 6 | $75.9M | 51 | -15.2% (-33.0% raw) | +22.1% (+8.8% raw) | -19.8% (-18.6% raw) | closed |
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.